BioSpace News Archive

P4 Diagnostix, a network of nationally-recognized diagnostic testing laboratories, today announced the acquisition of the assets of Strand Diagnostics, creator of the know error® system.

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), announced today that Dr. Brian Poligone, clinical investigator and lead enroller in the pivotal Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study evaluating SGX301 in the treatment of early stage cutaneous T-cell lymphoma

Marker Therapeutics, Inc. (NASDAQ: MRKR), today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on Marker’s planned trial investigating safety and efficacy of its novel MultiTAA T cell therapy in patients with post-transplant acute myeloid leukemia (AML).

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that the European Medicines Agency (EMA) has granted orphan drug designation to ION373 for the treatment of people with Alexander disease, a severe, progressive and debilitating condition that can eventually result in death due to loss of control over autonomic functions like breathing

Walgreens Boots Alliance announced the publication of its 2019 Corporate Social Responsibility Report, which details the company’s global sustainability initiatives, including efforts to improve access to quality healthcare, deliver support programs for people living with cancer and reduce its carbon footprint.

Biodesix, Inc. announced initiation of the next phase of their biomarker development program with Merck KGaA, Darmstadt, Germany and Pfizer Inc., New York, NY.

Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ solutions as prescription medical treatments, today announced the appointments of Muzammil Mansuri, PhD and Jeffrey Berkowitz as Senior Strategic Advisors, and the formation of a Payer Advisory Board, chaired by Mr. Berkowitz.

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2019 and provided guidance for 2020.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today the pricing of an underwritten registered public offering of 2,125,000 of its common shares at a price to the public of $4.00 per share

ZYUS Life Sciences Inc. (“ZYUS”), a company focused on the global development and commercialization of innovative cannabinoid-based formulations, announced that it has received both its Analytical Testing Licence and Research Licence from Health Canada in accordance with Canada’s Cannabis Act and Cannabis Regulations